{"id":53551,"date":"2024-07-18T08:00:00","date_gmt":"2024-07-18T06:00:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-ab-interim-report-q2-2024\/"},"modified":"2024-07-18T08:00:00","modified_gmt":"2024-07-18T06:00:00","slug":"stille-ab-interim-report-q2-2024","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-ab-interim-report-q2-2024\/","title":{"rendered":"Stille AB: Interim Report Q2 2024"},"content":{"rendered":"
\n

Stille AB (publ) today presents the report for the second quarter and first half of the year 2024.<\/strong><\/p>\n<\/div>\n

\n

Revenue amounted to MSEK 142.6 (75.1) driven by strong organic growth in surgical instruments and the acquisition of Fehling. Total growth amounted to 89.9 percent, of which 7.4 percent was organic growth.<\/p>\n

\u201cIt is encouraging to see that organic growth remains robust, despite strong comparable figures.\u201d<\/em>, says Torbj\u00f6rn Sk\u00f6ld and continues, \u201cWe are particularly pleased with the continued successful integration of Fehling and that our continual efforts <\/em>
<\/em>to improve our pricing, purchasing, production and quality are having a positive effect on our operations.\u201d<\/em><\/p>\n

The gross profit amounted to 49.3 percent (44.6) and operating profit before one-time costs amounted to MSEK 29.1 (11.9).<\/p>\n

\u201d2024 has continued on a high note \u2013 our products are delivering value to our customers, which is creating favorable demand, strong growth and a healthy cash flow.\u201d,<\/em> concludes Stille\u2019s CEO.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
MSEK<\/strong><\/td>\nAPR-JUN<\/strong>
<\/strong>2024<\/strong><\/td>\n		APR-JUN<\/strong>
<\/strong>2023<\/strong><\/td>\n		JAN-JUN<\/strong>
<\/strong>2024<\/strong><\/td>\n		JAN-JUN<\/strong>
<\/strong>2023<\/strong><\/td>\n		JUL-JUN<\/strong>
<\/strong>2023\/24<\/strong><\/td>\n		JAN-DEC<\/strong>
<\/strong>2023<\/strong><\/td>\n<\/tr>\n
Net sales<\/td>\n142.6<\/td>\n75.1<\/td>\n282.3<\/td>\n147.5<\/td>\n429.7<\/td>\n294.9<\/td>\n<\/tr>\n
Gross profit, %<\/td>\n49.3<\/td>\n44.6<\/td>\n48.9<\/td>\n43.5<\/td>\n50.2<\/td>\n44.8<\/td>\n<\/tr>\n
EBITDA before
non-recurring items<\/td>\n		36.0<\/td>\n15.7<\/td>\n69.6<\/td>\n29.4<\/td>\n102.8<\/td>\n62.6<\/td>\n<\/tr>\n
EBITDA before
non-recurring items, %<\/td>\n		25.2<\/td>\n20.9<\/td>\n24.7<\/td>\n20.0<\/td>\n23.9<\/td>\n21.2<\/td>\n<\/tr>\n
EBITDA<\/td>\n32.6<\/td>\n15.7<\/td>\n49.6<\/td>\n26.1<\/td>\n82.8<\/td>\n59.3<\/td>\n<\/tr>\n
EBITDA, %<\/td>\n22.9<\/td>\n20.9<\/td>\n17.6<\/td>\n17.7<\/td>\n20.0<\/td>\n20.1<\/td>\n<\/tr>\n
Operating profit before non-recurring items<\/td>\n29.1<\/td>\n11.9<\/td>\n56.1<\/td>\n22.4<\/td>\n81.9<\/td>\n48.3<\/td>\n<\/tr>\n
Operating profit before non-recurring items, %<\/td>\n20.4<\/td>\n15.9<\/td>\n19.9<\/td>\n15.2<\/td>\n21.0<\/td>\n16.4<\/td>\n<\/tr>\n
Operating profit<\/td>\n25.7<\/td>\n11.9<\/td>\n36.0<\/td>\n19.1<\/td>\n61.9<\/td>\n45.0<\/td>\n<\/tr>\n
Operating profit, %<\/td>\n18.0<\/td>\n15.9<\/td>\n12.8<\/td>\n12.9<\/td>\n15.1<\/td>\n15.2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Torsh\u00e4lla, July 18th, 2024.<\/p>\n<\/div>\n

\n

Contact Details<\/strong>
Torbj\u00f6rn Sk\u00f6ld<\/strong>
CEO & President
+46 (0)70 316 63 91 | torbjorn.skold@stille.se<\/a><\/p>\n<\/div>\n

\n

This information is information that Stille is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-18 08:00 CEST.<\/em><\/p>\n<\/div>\n

\n

About Us<\/strong>
Stille AB (publ) develops, manufactures and markets medical devices<\/strong> for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se<\/a>.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Interim Report Q2 2024<\/a><\/p>\n<\/div>\n